Major Study Points to COVID-19 Treatment; ‘Game Changer?”

COVID-19 remains a global crisis, particularly since we are moving into the more critical stage ("restart economy"), so please feel free to share this with anyone interested. Last evening, the world learned a Univ. of Chicago's Phase 3 trial of Gilead's (GILD) Remdesivir shows significant promise.
Remdesivir has been talked about for some time so I understand the skepticism, but the market has jumped 3% at the prospect.

Policymakers say a vaccine is key, but that could be six to 18 months awa...

Finish reading this report for free

Enter your email and we’ll send the paywall-free link directly to your inbox

In addition to your unlocked report, you will receive our weekly market newsletter FSI Snapshot, as well as occasional updates and offers from FS Insight. You can unsubscribe at any time. For more information, see our privacy policy.

Get unlimited access to Tom Lee’s Fundstrat research Subscribe
Already a member? Log in

More from the author

Disclosures (show)

Sign in to read the report!

We’ve detected that you have an active subscription!

Ray: 948831-6eabfc-f25f7e-1e2393-ca668c

Events

Trending tickers in our research